THANK YOU FOR SUBSCRIBING
Outset Medical, a San Jose, a CA-based commercial-stage company delivering technology into the global dialysis market, raised $132m in Series D equity financing led by new investor Mubadala Investment Company, Abu Dhabi’s leading investment company. Existing investors Baxter Ventures, the venture capital arm of Baxter International, Fidelity Management and Research Company, Partner Fund Management LP, Perceptive Advisors, funds advised by T. Rowe Price Associates Inc., and Warburg Pincus also participated.
The company intends to use the funds to increase production capabilities and accelerate the commercial expansion of its Tablo® Hemodialysis System in acute and chronic care markets in the United States.
Led by Leslie Trigg, Chief Executive Officer, Outset Medical provides the Tablo® Hemodialysis System which features real-time water purification and dialysis fluid production integrated into a single, compact system. It only requires an electrical outlet and tap water to operate.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The Tablo System is CE-marked and FDA-cleared for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company is conducting a clinical trial to expand Tablo’s labeled indication to include home use.
More in News